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Abstract 
Introduction: Leprosy is a skin disease that reaches 200,000 cases annually. Considered a 
neglected tropical disease, 80% of annual leprosy remained in countries such as Brazil, India, 
and Indonesia. Multi-drug treatment is effective in curing leprosy but ineffective in preventing 
further transmission. The implementation of large-scale single dose rifampicin-post exposure 
prophylaxis suggests the inhibition of leprosy transmission and thus needs validation. 
Methods: This systematic review was carried out based on the PRISMA statement from 
multiple databases using set keywords. A total of 646 studies were identified, followed by 4 
randomized controlled trials included after screening. 
Results: 86,502 subjects were divided into control and interventional groups and were to be 
followed-up in 2-6 years. Most studies showed a significant decrease of leprosy cases by 50-
60%. Furthermore, a complementary effect between single dose rifampicin-post exposure 
prophylaxis and Bacillus Calmette–Guérin vaccine was identified. Moreover, cost-
effectiveness of the intervention was analysed which resulted in IDR 80,414,775 being averted 
in its 25th year of implementation 
Conclusion: The review established promising results of implementing single dose rifampicin-
post exposure prophylaxis to prevent leprosy transmission. Further national scale intervention 
with a multi-layered approach is suggested to ensure full support and continuity of the large-
scale intervention 
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Introduction 
Leprosy, also known as Hansen’s 
disease, is a skin disease caused by 
Mycobacterium leprae that has been 
plaguing the earth since 600 BC. 
Previously known as kushta, the disease 
has been associated with different religious 
texts, affirming the earliest aetiology of the 
disease being due to a curse or misfortune. 
1,2 Only in 1873, the definitive cause of the 
disease was discovered by Dr. Genhard 
Armauer Hansen when he microscopically 
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observed a multiple rod-shaped bacillus 
while examining a skin biopsy of a leprosy 
patient.2 In the 21st century, new cases of 
leprosy reached 200,000 new cases 
annually which is a significant decrease 
compared to the 12 million new cases in 
1980. Despite the outstanding feat in 
intercepting transmission, the numbers 
have been stagnant for the past 8 years, 
signifying the still ongoing transmission of 
the disease. Currently, the disease is 
considered a neglected tropical disease 
(NTD) with countries such as Brazil, India, 
and Indonesia constituting 80% of the 
annual cases. Furthermore, the ongoing 
multidrug therapy (MDT) suggested by the 
World Health Organization (WHO) has 
been effective in alleviating symptoms of 
leprosy but not sufficient enough to prevent 
new cases of leprosy worldwide. This 
instance could be due to the decreasing 
resources being considered for leprosy 
worldwide and also antimicrobial and multi-
drug resistance that may rise due to the 
repeated and constant use of MDT on the 
bacteria. 2,3 
Moreover, this concern is 
exacerbated by the clustering of leprosy 
patients within endemic locations, 
translating to a high contact ratio between 
leprosy patients and the general public in a 
specific region, thus increasing the 
transmission rate of leprosy.2 In addition, 
due to the implicit nature of leprosy with 
long incubation periods, it remains a 
challenge to identify patients with leprosy 
without proper laboratory testing, 
increasing the general risk of the public that 
is unaware clinical signs of leprosy. Hence, 
there is an urgent need for an alternative or 
an additional intervention that does not only 
react to leprosy, but also act as a 
preventive measure against leprosy 
transmission.3 
As a response, the implementation 
of large-scale immune-prophylaxis or 
chemoprophylaxis has been suggested but 
still not fully available, one of them being 
the administration of single dose rifampicin 
as a post-exposure prophylaxis (SDR-
PEP). By adopting a pre-emptive ‘blanket’ 
approach, the large-scale administration 
may aid in preventing leprosy transmission. 
Thus, this systematic review was made 
with the purpose of analysing the 
effectiveness of previous SDR-PEP 
randomized controlled trials and to validate 
its prospective feasibility as a preventive 
measure for leprosy treatment especially in 
Indonesia. By doing so, the group of 
authors hopes to contribute to the WHO 
formulated roadmap to combat the now 17 
NTDs and to help in realising the 
sustainable development goals (SDG) 
number 3, specifically target 3.3 which is to 
eradicate infectious and tropical diseases 




 For this systematic review, 
literature search was carried out according 
to the Preferred Reporting Items for 
Systematic Review and Meta-Analysis 
(PRISMA). The following keywords were 
used to obtain relevant studies for this 
review; “Leprosy” AND (“Prophylaxis” OR 
“post exposure prophylaxis” OR 
“chemoprophylaxis”) AND (“Single dose 
rifampicin” OR “Rifampicin”) AND 
(“Prevention” OR “Feasibility”), utilising 
synonyms and implementing Medical 
Subject Headings (MeSH) where 
appropriate. Search strategy was 
conducted on 5 main databases namely: 
PubMed/MEDLINE, Science Direct, 
CENTRAL/Cochrane, Wiley Online Library, 
and Directory of Open Access Journals 
(DOAJ) for peer-reviewed studies 
published up to 12 March 2021. 
 
Inclusion & Exclusion Criteria 
 Throughout the synthesis of this 
paper, the inclusion criteria used were as 
follows: (1) study design being randomized 
controlled trials (RCT); (2) population 
endemic of leprosy or is in close contact 
with leprosy patients; (3) intervention in the 
form of SDR-PEP; (4) use of placebo or 
other intervention strategies for control; (5) 
outcome in the form of clinical 
manifestation of leprosy and incidence 
reduction where appropriate. While the 
exclusion criteria applied were: (1) Studies 
with irretrievable full text; (2) non-research 
articles such as reviews, advertorials, and 
conference abstracts; (3) Studies in 
languages other than Bahasa Indonesia, 
Thai, Chinese, and English. 
 




Data Extraction and Study Outcomes 
Two independent reviewers 
conducted data extraction, with differences 
adjudicated by consensus from a separate 
third investigator. The information 
extracted from the included studies were: 
(1) author and year of publication; (2) study 
characteristics: location and design; (3) 
study population: sample size and subject 
characteristics; (4) interventions used; (5) 
follow-up period of study. Primary outcome 
from this study was the (1) clinical 
manifestation of leprosy with secondary 
outcomes being (2) incidence rate and (3) 
reduction in incidence. 
 
Risk of Bias Assessment 
Risk of bias (ROB) assessment was 
conducted using the Cochrane risk-of-bias 
tool for randomized controlled studies 2.0 
to evaluate methodological quality.5 The 
ROB assessment tool has 5 main domains 
with each addressing the bias risk 
potentially arising from: randomization 
process, multiple deviations from the 
intended interventions, missing data, bias 
in outcome measurement, bias is result 
reporting. Response options were 
recorded in Yes, Probably Yes, Probably 
No, No, and Not Included which evaluates 
each domain to show low, some, or high 
risk of bias according to Agency for 
Healthcare Research and Quality (AHRQ). 
The assessment was performed separately 
by three independent investigators, with 
discrepancies being resolved by mutual 




Search carried out on five 
international databases applying the set 
keywords resulted in 646 studies before 
screening. The 646 studies were then 
further evaluated via the examination of 
their title and abstract to ensure relevancy. 
After initial screening, 21 records were 
identified and 9 records after duplicates 
were excluded. Full-text screening was 
conducted on the 9 studies, resulting in 5 
studies being excluded due to having 
irretrievable text and incompatible study 
design not relevant to this review. The full 
search strategy is shown as a PRISMA 
flowchart diagram in Figure 1. 
 
Characteristics of Included Studies 
Careful screening according to the 
inclusion and exclusion criteria resulted in 
4 single centre RCTs conducted in 
Bangladesh with 3 of them being double-
blinded for their methodological process. In 
total, 86,502 subjects were tested which 
were close contacts of leprosy patients in 
endemic populations with effectiveness 
indicated by the number of clinical leprosy 
development after follow-up as the primary 
outcome. Two of the studies tested the 
effectiveness of SDR-PEP compared to a 
control group exclusively while the other 
two decided to test the effectiveness of 
SDR-PEP administration post Bacillus 
Calmette–Guérin (BCG) vaccination. 
Furthermore, all of the studies decided on 
2 years as the most optimal follow-up 
period while 2 studies decided to continue 
follow-up up to 6 years despite the results 
not being particularly significant. The 4 
RCTs were assessed using the Cochrane 
Risk-of-Bias tool 2.0 with 3 studies 
achieving good quality while one having fair 
quality due to not being able to conduct 
double blinding within its trial. The 
complete summary table of study 
characteristics and outcome is shown as 
Table 1. while the summarised ROB shown 
as Table 2. 6-9
 
 










Current state of Multi Drug Therapy (MDT) 
on Leprosy 
The combination of dapsone, 
clofazimine, and rifampicin or collectively 
called MDT has been coined the treatment 
of choice for leprosy by the WHO since the 
1940’s.6 Combined, the administration of 
the drug  according to the WHO protocol 
yielded an overall efficacy rate of 60% and 
has succeeded in pressing the global 
concern of the disease, placing it under the 
category of NTD.5,10 Despite that, the 
treatment has gained much scepticism 
regarding its effectiveness by 
dermatologist from countries endemic for 
leprosy due to its long duration of 
treatment.10 Other than inducing drug 
resistance among  Mycobacterium leprae, 
the effectiveness of the chemotherapy has 
remained stagnant shown by the 
unchanging trend and detection rate of 
leprosy over the past 70 years.8 On the 
other hand, novel treatments  such as the 
administration of SDR-PEP has been 
shown to interrupt the transmission chain of 
M.leprae by 57% if given pre-emptively to 
close contact of leprosy patients, providing 
them innate protection against leprosy 
infection.6-10 Hence, to anticipate the 
declining effectiveness of sole MDT as the 
golden standard treatment for leprosy, 
other potential alternatives taken from a  
different approach such as SDR-PEP are 
required to be explored extensively. 
 
The potential of Single Dose Rifampicin -  
Post Exposure Prophylaxis (SDR-PEP) 
Leprosy as an infectious disease 
has been a hurdle for practitioners to 
intervene due to its elusive nature, long 
incubation period, and difficulty in clinical




Table 1. Complete Summary of Study Characteristics and Outcome 
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52/6,470 N/A N/A N/A 
BCG Vaccination 
only (n=4,306) 
15/4,306 N/A 57 (24-75) <0.05 
150 mg SDR-PEP 
capsules only 
(n=6,484) 
22/6,484 N/A 58 (30-74) <0.05 
BCG vaccination + 
150 mg SDR-PEP 
capsules (n=4,266) 
7/4,266 N/A 80 (50-92) <0.05 
Legend: SDR: Single Dose Rifampicin; BGC: Bacillus Calmette–Guérin; CI: Confidence Interval 




Table 2. Summary of Bias Assessment using RoB 2 
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diagnosis. Being a skin disease, leprosy is 
commonly associated with a defined skin 
lesion with loss of sensation, visible surface 
deformities on the skin, and the loss of 
sensation or malaise of the extremities due 
to the thickening of the patient’s nerve. 
Although, those symptoms only manifest 
after 5 years of incubation in which the 
patient will be asymptomatic but tested 
positive by polymerase chain reaction 
(PCR) for the bacteria and is able to 
transmit the bacteria towards their close 
contacts.11 Rifampicin or rifampin (3-(4-
methyl-1-piperazinyl)-imino-methyl 
rifamycin) is a drug that targets the 
deoxyribonuclease acid (DNA) replication 
process of the bacteria. Also considered 
under post-exposure prophylaxis (PEP) 
due to its property as an anti-Human 
immunodeficiency virus (anti-HIV) 
treatment, the drug specifically targets the 
β-subunit of the DNA-dependent 
ribonuclease acid (RNA) polymerase, 
preventing the subunit from binding with the 
bacteria’s DNA and inhibiting mRNA 
transcription. With crucial genes not being 
transcribed, this leads to the inhibition of 
essential proteins for the bacteria to be 
translated, and thus initiating cell death.12 
By utilising a ‘blanket group’ approach, in 
which cost-effective treatments are 
administered in a large scale over an 
endemic area, more people, infected-or-
not, are given a baseline protection that 
may protect them from the manifestation of 
leprosy especially during its pre-
manifestation period.7-12  
 
Effectiveness analysis of Single Dose 
Rifampicin – Post Exposure Prophylaxis 
(SDR-PEP) 
From the 5 included studies, 
effectiveness of the treatment is 
predominantly determined by comparing 
the number of subjects that developed 
leprosy between the SDR-PEP group and 
the control group. Leprosy diagnosis was 
mostly confirmed by a medical or leprosy 
control officer that has at least 5 years of 
experience in diagnosing patients with 
leprosy. Generally, the SDR-PEP group in 
all the controlled studies showed fewer 
manifestation of clinically identified leprosy 
after follow up.6-9 Studies conducted by 
Moet et al and Feenstra et al showed that 
the incidence rate of the SDR-PEP group to 
be half of the control group, with incidence 
reduction achieving 56.5% [32.9,71.9] 
(p=0.0002) and 39% respectively.6,8 
Moreover, the same two studies also 
implemented follow-up periods of more 
than 2 years in which incidence reduction 
between the SDR-PEP and control group 
became less obvious and insignificant.6,8 
However, despite the small incidence 
reduction of only 5.1 % [0.6,9.5], Feenstra 
      
      
      








et al reported the findings to be statistically 
significant (p=0.025), indicating the SDR-
PEP group is still better in preventing 
leprosy development.8 This finding 
provides valuable insight in determining the 
effective frequency of population wide 
SDR-PEP administration in ensuring 
maximal suppression of leprosy 
transmission. Furthermore, the 
administration of SDR-PEP as 
chemoprophylaxis following BCG 
immunization as an immune-prophylaxis 
according to Schuring et al proved 
impressive results with an incidence 
reduction of 80% [50,92] (p<0.05), followed 
by Richardus et al’s study with 42 % [13,70] 
(p=0.148).9 This finding is further supported 
by complementary reactional-effect 
suggested by the meta-analysis written by 
Schoenmakers et al. on the additive 
property of immune-prophylaxis and 
chemoprophylaxis in leprosy.13  
 
Applicability and cost effectiveness in 
Indonesian context 
 All four of the included studies were 
conducted in Bangladesh. 
Demographically, the regions endemic for 
leprosy in Bangladesh and Indonesia would 
show similar characteristics as they belong 
in a lower to middle income family.5,7 
Furthermore, another study conducted by 
Tiwari et al. evaluated the cost-
effectiveness aspect of the SDR-PEP 
treatment in accordance with the Indian 
health system. From that study, it was 
estimated that each administration of SDR-
PEP would avert US$ 2.9 or about IDR 
41,107 and prospectively avert US$ 5,673 
or IDR 80,414,775 in the 25th year since its 
initial implementation.14,15 Bringing this into 
perspective, SDR-PEP or 
chemoprophylaxis in general has been 
pioneered by certain non-governmental 
organisations (NGO) that values the same 
goal of eradication leprosy and partnered 
with the Global Partnership for Zero 
Leprosy coalition. An example includes the 
Netherland Leprosy Relief (NLR) which is 
an NGO which has been introducing 
chemoprophylaxis in five different regions 
of Indonesia. Furthermore, similar NGOs 
have also developed leprosy-friendly 
village models where primary healthcare 
personnel are more sensitised to early 
signs of leprosy symptoms, hence enabling 
them to identify potential leprosy carriers 
and administer SDR-PEP sooner.16 
Currently in Indonesia, treatment for 
leprosy patients still includes Multi Drug 
Treatment of Leprosy (MDTL) which are 
divided into two regimens: paucibacillary 
(PB) leprosy type and Multibacillary (MB) 
leprosy type. Although, research on SDR-
PEP implementation have been carried out 
with prospective results 5 years from now. 
Hence, SDR-PEP is a cost-effective 
strategy in the short and long term and is 
highly applicable in Indonesia based on the 
sample familiarity and current additional 
preventive effort being carried out in the 
country.17 
 
Study strength and limitations 
 The strength of this review lies in 
the uniformity of the study design across 
the four studies; with all being large 
randomised controlled trials and 3/4 being 
double-blinded. This homogeneity made 
the studies easily comparable and thus 
helped in forming links between them and 
synthesising justified conclusions. 
Furthermore, RCTs are commonly referred 
to as the golden standard for evidence-
based medicine which is further 
strengthened by the elimination of 
selection, observational, and participant 
bias from double blinding. Moreover, the 
long period of follow-ups allows the 
definitive analysis of outcome in the short 
and long term. However, this systematic 
review is limited by the lack of variability in 
study locations and different control groups 
of each study. This difference may affect 
the comparison between the reduction in 
incidence values, making those 
comparisons not representative. 
Nevertheless, this can be compensated by 
firstly comparing and analysing studies with 
similar control groups in a meta-analysis.  
 
Conclusion 
In conclusion, leprosy has remained 
a prevalent problem in certain corners of 
the world, one of them being in Indonesia. 
The nationwide implementation of MDTs 
has been a huge success in curing and 
cutting the numbers of leprosy cases, but 
remained insufficient in inhibiting the steady 
transmission of the disease. The 




introduction of SDR-PEP as a cost-efficient 
and effective preventive method against 
leprosy transmission has shown promising 
results with 50-60% incidence reduction 
among endemic leprosy populations. By 
using a ‘blanket’ approach towards 
segmented regions that are considered 
leprosy clusters, transmission can be 
prevented prematurely and hence lowering 
the annual cases of leprosy. However, 
considering the limitations of this review, 
the author recommends more studies to be 
conducted in different countries endemic to 
leprosy and a review on biosafety of SDR-
PEP towards various populations. 
In the implementation of the 
treatment, we recommend a multi-layered 
approach with multiple stakeholders to be 
involved in the dissemination of SDR-PEP.  
This approach is conducted by considering 
several suggestions which includes: Firstly, 
commitment of the local governance is 
necessary to ensure continuous support of 
the intervention. Secondly, structured 
planning, monitoring, and evaluation needs 
to be agreed upon before the execution. 
Thirdly, if possible, integrate SDR-PEP into 
pre-existing leprosy prevention systems 
especially regarding contact tracing and 
surveillance. Lastly, to coordinate the 
execution with established health 
institutions to certify proper publication and 
prospective analysis of the intervention. 
These recommendations are essential in 
establishing an effective public health 
approach against leprosy in Indonesia and 
thus achieving SDGs in terms of 
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